The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Translational research in Berlin to improve AML treatment outcomes
New research methods enable a greater understanding of a disease and allow for more personalized medicine to be produced. In this interview, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, speaking from the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), discusses ongoing translational research in Berlin to characterize acute myeloid leukemia (AML) in all age ranges, with a multitude of aims, including identifying biomarkers and treatment responses, in addition to improving the registries storing this data. Dr Bullinger also describes how he foresees cellular immunotherapies being utilized to treat persistent AML.
